![logo](/logos/GLENMARK.NS.webp)
Glenmark Pharmaceuticals Limited
NSE:GLENMARK.NS
1,702.7 (INR) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Glenmark Pharmaceuticals Limited |
Symbool | GLENMARK.NS |
Munteenheid | INR |
Prijs | 1,702.7 |
Beurswaarde | 480,481,507,600 |
Dividendpercentage | 0.25% |
52-weken bereik | 722.1 - 1,750.5 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. Glenn Mario Saldanha |
Website | https://www.glenmarkpharma.com |
An error occurred while fetching data.
Over Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab),
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (INR)
Cijfers zijn in miljoenen (INR)